Targeting RANKL in metastasis.

Area of Science:

• Oncology
• Bone Biology
• Metastasis Research

Background:

• Receptor activator of nuclear factor-κB ligand (RANKL) is crucial for osteoclast function and survival.
• RANKL blockade inhibits tumor-induced osteoclastogenesis, protecting against bone destruction and skeletal-related events (SREs).
• Denosumab, an anti-RANKL antibody, prevents SREs in patients with bone metastases.

Purpose of the Study:

• To review the mechanisms by which RANKL promotes bone metastases.
• To explore the direct pro-metastatic effects of RANKL independent of osteoclasts.
• To discuss the potential of RANKL inhibition in reducing both bone and distant metastases.

Main Methods:

• Review of preclinical data on RANKL inhibition and bone metastases.
• Analysis of clinical data on denosumab efficacy in preventing SREs.
• Examination of emerging evidence on RANKL's direct effects on cancer cells.

Main Results:

• RANKL inhibition protects against bone destruction and delays bone metastasis formation.
• Denosumab prevents or delays skeletal-related events in cancer patients with bone metastases.
• RANKL directly stimulates cancer cell invasion and migration via RANK-expressing cancer cells, independent of osteoclasts.

Conclusions:

• RANKL plays a dual role in cancer metastasis: mediating osteoclast activity and directly promoting cancer cell invasion.
• Targeting RANKL offers a therapeutic strategy to combat both bone destruction and the spread of cancer to distant sites.
• Further research into the direct anti-metastatic effects of RANKL inhibition is warranted.